SUPN
NasdaqSUPERNUS PHARMACEUTICALS, INC.
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$579.8M
2021
$667.2M
2022
$607.5M
2023
$661.8M
2024
$719.0M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$719.0M
Net Income$-38.6M
Gross Profit—
Oper Income$-62.3M
EPS (dil)$-0.68
Rev/sh$12.39
FCF/sh$0.79
Book/sh$18.29
Gross M—
Oper M-8.7%
Profit M-5.4%
FCF M6.4%
ROE-3.6%
ROA-2.7%
ROIC-3.7%
R&D/Rev14.8%
Rev Y/Y8.6%
Rev 3Y CAGR2.5%
EPS Y/Y-151.5%
EPS 3Y CAGR—
FCF 3Y CAGR-26.6%
Payout—
Div/sh—
Shs Chg Y/Y+0.9%
Current Ratio1.90
Quick Ratio1.57
Debt/Eq0.38
Int Coverage—
Net Debt$271.5M
Total Debt$401.4M
Cash & Eq$129.9M
Total Assets$1.5B
Oper CF$47.3M
Capex$1.3M
Free CF$46.0M
Buybacks—
Equity$1.1B
Liabilities$390.9M
Shs Outstand0.06B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $579.8M | $667.2M | $607.5M | $661.8M | $719.0M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $86.0M | $46.1M | $-5.3M | $81.7M | $-62.3M |
| Net Income | $53.4M | $60.7M | $1.3M | $73.9M | $-38.6M |
| Diluted EPS | $0.98 | $1.04 | $0.02 | $1.32 | $-0.68 |
| Operating Cash Flow | $127.1M | $116.8M | $111.1M | $172.0M | $47.3M |
| Free Cash Flow | — | $116.4M | $110.5M | $171.2M | $46.0M |
COMMUNITY · $SUPN0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.